A lawsuit was filed on behalf of investors in Sema4 Holdings Corp. (NASDAQ:SMFR) shares over alleged securities laws violations.

San Diego, CA -- (SBWire) -- 09/22/2022 --An investor, who purchased shares of Sema4 Holdings Corp. (NASDAQ: SMFR), filed a lawsuit over alleged Securities Laws violations by Sema4 Holdings Corp.

Investors who purchased shares of Sema4 Holdings Corp. (NASDAQ: SMFR) between March 14, 2022 and August 15, 2022, and / or if you purchased any NASDAQ: SMFR shares prior to March 2022 and continue to hold any of those shares, yo have certain options and for certain investors are short and strict deadlines running. Deadline: November 7, 2022. NASDAQ: SMFR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Stamford, CT based Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data.

On February 10, 2021, -Sema4 and CM Life Sciences (Nasdaq: CMLF) announced they have entered into a definitive business combination agreement. Under the terms of the agreement, CM Life Sciences shareholders will retain ownership of only 17% of the combined company.

On July 22, 2021, CM Life Sciences, Inc., a special purpose acquisition company, completed its business combination with Mount Sinai Genomics, Inc., and the combined public entity was renamed Sema4 Holdings Corp.

On June 14, 2022, Sema4 Holdings Corp announced that its Chief Financial Officer had departed.

On August 15, 2022, after the market closed, Sema4 Holdings Corp announced changes to its research and development leadership team, including that its founder was stepping down from the organization and leaving his role as President and Chief R&D Officer. The Company also disclosed that it was eliminating approximately 13% of its workforce as part of a series of restructuring and corporate realignments. Additionally, Sema4 lowered its fiscal 2022 revenue guidance to $245 million to $255 million from its prior guidance of $305 million to $315 million.

The plaintiff claims that between March 14, 2022 and August 15, 2022, the Defendants failed to disclose to investors that there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third party payors, that the Company was experiencing declining selling prices for its reproductive health segment, that, as a result of the foregoing, Sema4's financial results would be adversely affected, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Sema4 Holdings Corp. (NASDAQ: SMFR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.